Skip to main content

Advertisement

Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Fig. 1

Patient assignment to different protocols. a Post-induction treatment assignment criteria (Arm A, Arm B, Arm C). b Response-based treatment reassignment algorithm for NCI standard-risk patients initially assigned to induction Arm A. Patients who were M2/M3 (≥ 5% blasts) at day 15 or MRD% ≥ 0.01 at day 29 were reassigned to Arm C. Patients thus reassigned who were still at MRD% ≥ 0.01 at end-of-consolidation were taken off protocol as induction failure. Remaining patients continued on Arm A. c Response-based treatment reassignment algorithm for NCI high-risk patients initially assigned to induction Arm B. Induction Arm B patients who were day 29 MRD% ≥ 0.01 were either taken off protocol (if MLLR) or reassigned to post-induction Arm C (if B-cell) or Arm C + HDMTX (if T-cell). At end-of-consolidation, patients on Arm C with MRD% ≥ 0.01 were taken off protocol as induction failure. d Algorithm for patients initially assigned to induction Arm C or switched from induction Arm A or B to Arm C. Arm C patients who were M3 on day 29 were taken off protocol as induction failure. M2 patients who also had MLLR were also taken off protocol. T-cell patients were supplemented with HDMTX. The remainder continued on Arm C until end-of-consolidation, whereupon those who were MRD% ≥ 0.01 were taken off protocol

Back to article page